Stemcells +200%!!! - 500 Beiträge pro Seite

[meislo]

StemCells Inc. Product Study Yields Positive Results
Friday May 2, 9:10 am ET


PALO ALTO, Calif. (Dow Jones)--StemCells Inc. reported encouraging findings from a preclinical study that evaluated the company`s human neural stem cell technology, or hCNS-SC, as a means to regenerate damaged nerves and nerve fibers in patients with spinal cord injuries.
ADVERTISEMENT


"The potential significance of this study is that we may be able to help those with spinal cord injuries regain their mobility," stated Martin McGlynn, president and chief executive of StemCells.

In a press release Friday, the biomedical company said injured mice transplanted with its hCNS-SC showed improved motor function in tests designed to measure functional recovery.

The study also made a direct link between the amount of functional recovery and the level of cell engraftment.

Also, the study found that hCNS-SC does not contribute to scarring due to glial cell proliferation, which normally inhibits neuronal cell growth and recovery.

"The sample size in these pilot studies is small. However, we are particularly encouraged by the consistent trend for the transplanted animals to perform better than their controls. Our task now is to replicate these studies and to evaluate the potential of these hCNS-SC at different dose levels," noted one of the study`s presenters, Dr. Brian Cummings.

[meislo]

Stammzellen-aktien scheinen so langsam wieder in Mode zu kommen nachdem Geron und nun Stemcells positive Ergebnisse in den frühen klinischen Phasen ermutigende Ergebnisse lieferten. Am Wochenende ist eine Bio-konferenz auf der Gerons Kooperationspartner, das Duke Medicalcenter, ebenfalls über Rückenmarkbehandlungen verletzter Nervenstränge mit ES berichten wird. Bin mal gespannt was da rauskommt


Stem cell firms surge, sector edges up

By Ted Griffith, CBS.MarketWatch.com
Last Update: 10:02 AM ET May 2, 2003







NEW YORK (CBS.MW) -- Shares of two biotech firms involved with stem cell research were sharply higher in early trading Friday after researchers at the University of Pennsylvania announced a discovery that could remove obstacles to the controversial research.





Free! Sign up here to receive our Midday Market Report e-Newsletter!




INFORMATION FOR GERN:
Create an alert for GERN

Add GERN to my portfolio

More cool charts on GERN

Discuss GERN
NEWS FOR GERN
BioSite, Northwest Airlines, StemCells, and more
Stem cell firms surge, overall biotech sector up
Avocent, Rambus, SupportSoft, and more
More news for GERN

Quote & News Charts Financials Analysts Options SEC Filings




TRACK THESE TOPICS
My Portfolio Alerts
Company: Stemcells Inc Add
Create
Column: Biotech Stocks
Create
Company: Geron Corporation Add
Create
Index: Biotechnology Index Add
Create

Get Breaking News sent directly to your inbox




Create A Portfolio | Create An Alert





Shares of StemCells Inc. (STEM: news, chart, profile) rocketed $1.28, or 173 percent, to $2.02 shares of Geron (GERN: news, chart, profile) gained 26 cents, or 6 percent, to $4.81.

A University of Pennsylvania study found that it may be possible to coax embryonic stem cells to transform themselves into eggs, holding out the possibility that an abundant source of eggs for the research could be established. It also appears that the eggs could be genetically engineered to prevent the production of a cloned baby while still allowing scientists to pursue cloning for therapeutic purposes.

Separately, StemCells announced that it had some success in repairing nerve damage in very early-stage testing on mice.

Overall, biotech stocks were moving higher. The Amex Biotechnology Index (BTK: news, chart, profile) rose 1.2 percent and the Nasdaq Biotechnology Index (NBI: news, chart, profile) gained 0.9 percent.


gruss meislo